Article

physIQ Announces Collaboration with InCarda Therapeutics and Syneos Health

physIQ has announced a strategic collaboration with InCarda Therapeutics, Inc. Syneos Health recommended physIQ’s monitoring solution to help advance InCarda’s clinical study of InRhythm™ (orally inhaled flecainide) in patients with atrial fibrillation.

Read more about the new partnership here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
Related Content
Dynavax Technologies’ Investigational Shingles Vaccine Achieves Complete Antibody Response in Phase I/II Shingles Trial
August 24th 2025

Dynavax Technologies’ Investigational Shingles Vaccine Achieves Complete Antibody Response in Phase I/II Shingles Trial

Don Tracy, Associate Editor
ACT Brief Episode 5: How Digital Twins and AI Are Reshaping Clinical Trials
August 24th 2025

ACT Brief Episode 5: How Digital Twins and AI Are Reshaping Clinical Trials

Andy Studna, Senior Editor
© Production Perig - © Production Perig - stock.adobe.com
August 24th 2025

Phase II Trial Launches of Anktiva in Long COVID Patients

Andy Studna, Senior Editor
ACT Brief Episode 4: New Data on Trial Delays, Hybrid Payment Models, and Managing Complexity
August 24th 2025

ACT Brief Episode 4: New Data on Trial Delays, Hybrid Payment Models, and Managing Complexity

Andy Studna, Senior Editor
© Pixel-Shot - © Pixel-Shot - stock.adobe.com
August 24th 2025

NCX 470 Meets Phase III Goal in Glaucoma With Strong Intraocular Pressure Reductions

Andy Studna, Senior Editor
FDA Lifts Clinical Hold on Rocket Pharmaceuticals’ Phase II Novel Investigative Gene Therapy Trial for Danon Disease
August 24th 2025

FDA Lifts Clinical Hold on Rocket Pharmaceuticals’ Phase II Novel Investigative Gene Therapy Trial for Danon Disease

Don Tracy, Associate Editor
© 2025 MJH Life Sciences

All rights reserved.